The future of Pharma R&D

R&D has always been essential and will likely become much more so in the future for the expansion and success of research-based pharmaceutical enterprises. The pharmaceutical business is currently going through a time of great transformation and uncertainty, which is characterised by increased R&D expenses, depleted pipelines, and financial constraints on performing novel research. All of this is made worse by the global economic crunch, which has resulted in an increase in layoffs and budget cuts for research. However, huge crises can occasionally lead to major possibilities. Through the sharing of risk, cost, and intellectual property through R&D strategic alliances involving all types of innovators, such as pharmaceutical, biotechnology, academic drug-discovery centres, and clinical research organisations, new business models such as open innovation may help resolve the so-called pharmaceutical "productivity paradox."

 

    Related Conference of The future of Pharma R&D

    July 25-26, 2024

    4th International Conference on Biomedicine & Pharmacotherapy

    Prague, Czech Republic

    The future of Pharma R&D Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in